Amring Pharmaceuticals Inc. Acquires LYSTEDA®

·2-min read

Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical company, announced entering into an agreement with Ferring International Center S.A. on December 1, 2020 that will further strengthen its position in the marketplace with the acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB). Amring has been marketing the authorized generic version of LYSTEDA in the USA since March 14, 2016.

"With the acquisition of LYSTEDA, Amring is further securing its position as a market leader in the treatment of HMB and expands product opportunities in markets outside of the USA," stated Daniel Carbery, President and CEO of Amring. "We believe that this brings long term value to patients and customers in our target markets."

About Amring Pharmaceuticals Inc.

Amring Pharmaceuticals is a privately held pharmaceutical company that provides value brands and niche generics to the market. The company is part of Sever Life Sciences, BV and is partnered with well-established global biopharmaceutical companies. Amring is uniquely positioned to leverage its partners’ expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

About Ferring International Center S.A.

Ferring International Center S.A. is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.

For more information on Ferring International Center S.A., please visit: https://www.ferring.com.

Safe Harbor

This press release contains forward-looking statements, including, without limitation, statements related to Amring’s business developments and the implementation of Amring’s strategic initiatives. Because these statements reflect Amring’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring’s business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005963/en/

Contacts

Amring Pharmaceuticals Inc.
Marina Volin, General Counsel
610.285.7137
marina.volin@amringpharma.com